INHIBRX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet…

Item 1.01 Entry Into a Material Definitive Agreement

On October 3, 2022, Inhibrx, Inc. (the "Company") and Oxford Finance LLC("Oxford") entered into a sixth amendment (the "Sixth Amendment") to the Loanand Security Agreement between the Company and Oxford, dated as of July 15,2020, as amended by the First Amendment dated November 12, 2020, the SecondAmendment dated December 15, 2020, the Third Amendment dated June 18, 2021, theFourth Amendment dated February 18, 2022, and the Fifth Amendment dated June 15,2022 (collectively, the "Oxford Loan Agreement").

The Sixth Amendment amends and restates the Seventh Draw Period (as originallydefined in the Fourth Amendment) to be the period commencing on the later of (i)June 30, 2022 and (ii) the date of the occurrence of the FDA Announcement Event(as defined in the Sixth Amendment), and ending on the earliest of (i) December31, 2022, (ii) the date that is thirty (30) days immediately after theoccurrence of the FDA Announcement Event and (iii) the occurrence of an Event ofDefault (as defined in the Loan and Security Agreement); provided, however, thatthe Seventh Draw Period shall not commence if on the date of the occurrence ofthe FDA Announcement Event an Event of Default has occurred and is continuing.

Except as noted above, the terms of the Oxford Loan Agreement remain unchanged.

The foregoing description of the Sixth Amendment is qualified in its entirety byreference to the Sixth Amendment attached as Exhibit 10.1 to this Current Reporton Form 8-K and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under anOff-Balance Sheet Arrangement of a Registrant

The information set forth in Item 1.01 of this Current Report on Form 8-K isincorporated by reference herein.

Item 7.01 Regulation FD Disclosure.

On October 4, 2022, the Company posted an updated copy of its corporate slidepresentation to the "Investors" tab of its website at http://www.inhibrx.com. Theseslides are also attached to this Current Report on Form 8-K as Exhibit 99.1. TheCompany from time to time presents and/or distributes to the investmentcommunity at various industry and other conferences slide presentations toprovide updates and summaries of its business. It undertakes no obligation toupdate, supplement or amend the materials attached hereto as Exhibit 99.1.

Item 8.01 Other Events.

On October 4, 2022, the Company issued a press release announcing the potentialto pursue an accelerated approval pathway in the United States for INBRX-101, anoptimized recombinant human AAT-Fc fusion protein, in patients with emphysemadue to alpha-1 antitrypsin deficiency (AATD). The Company also announced thedetection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) data in allAATD patients tested in its Phase 1 study. The full text of the Company's pressrelease regarding this announcement is filed as Exhibit 99.2 to this CurrentReport on Form 8-K and incorporated herein by reference.

The information in Item 7.01 of this Current Report on Form 8-K, includingExhibit 99.1 attached hereto, is intended to be furnished and shall not bedeemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934(the "Exchange Act") or otherwise subject to the liabilities of that section,nor shall it be deemed incorporated by reference in any filing under theSecurities Act of 1933 or the Exchange Act, except as expressly set forth byspecific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

--------------------------------------------------------------------------------

Edgar Online, source Glimpses

More:
INHIBRX, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet...